KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $38050.0.

  • Sarepta Therapeutics' Gains from Sales and Divestitures fell 6095.83% to $38050.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $38050.0, marking a year-over-year decrease of 6095.83%. This contributed to the annual value of $734922.0 for FY2024, which is 1400.96% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Gains from Sales and Divestitures of $38050.0 as of Q3 2025, which was down 6095.83% from $38050.0 recorded in Q2 2025.
  • Sarepta Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $734922.0 during Q4 2024, with a 5-year trough of $38050.0 in Q2 2025.
  • Its 5-year average for Gains from Sales and Divestitures is $301363.6, with a median of $276980.0 in 2021.
  • In the last 5 years, Sarepta Therapeutics' Gains from Sales and Divestitures surged by 6995.77% in 2021 and then tumbled by 7532.5% in 2024.
  • Sarepta Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $276980.0 in 2021, then soared by 40.72% to $389761.0 in 2022, then skyrocketed by 65.39% to $644614.0 in 2023, then rose by 14.01% to $734922.0 in 2024, then tumbled by 94.82% to $38050.0 in 2025.
  • Its Gains from Sales and Divestitures was $38050.0 in Q3 2025, compared to $38050.0 in Q2 2025 and $734922.0 in Q4 2024.